August 18, 2025 — Leads & Copy — Genflow Biosciences Plc has released an update on its Dog Aging (GF-1004) study, a clinical trial assessing the safety and efficacy of its SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The trial involves 28 beagles aged 10+ years, with recipients receiving three modalities of SIRT6 gene therapy without adverse effects.
The dogs will now undergo a five-month follow-up period expected to conclude in January 2026. The goal of the trial is to generate preclinical data that will enable a licensing agreement with an animal health company. GF-1004 targets aging mechanisms shared by dogs and humans, offering the potential to extend lifespan and improve the quality of life in companion animals.
Study objectives include confirming the feasibility of GF-1004 administration, validating safety and efficacy at the proposed dose, and demonstrating benefits relevant to clinical outcomes and consumer appeal.
Dr. Eric Leire, CEO of Genflow, stated that the absence of adverse events confirms the treatment’s safety profile. The company is focused on advancing GF-1004 to secure a partnership with an animal health company.
Contacts:
Genflow Biosciences
Harbor Access
Dr Eric Leire, CEO
Jonathan Paterson, Investor Relations
+32-477-495-881
+1 475 477 9401
Jonathan.Paterson@Harbor-access.com
Corporate Brokers
Capital Plus Partners Ltd
Jon Critchley, +44 207 432 0501
Source: Genflow Biosciences
